Ortho HBsAg System 3 BLA gains approval
This article was originally published in The Gray Sheet
Executive Summary
Third-generation enzyme-linked immunosorbent assay to detect hepatitis B surface antigens in human serum or plasma includes color-coded microplate rims and a sample omission monitor as a process control enhancement, according to Raritan, N.J.-based Ortho-Clinical Diagnostics, which announced the approval May 5. The firm touts the new screening assay as having both increased specificity (0.10 ng/mL) and sensitivity (99.97%) and says it plans to phase out the second-generation product gradually as clients opt for upgrades...
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.